Tower Research Capital LLC (Trc) Sesen Bio, Inc. Transaction History

Tower Research Capital LLC (Trc)

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.49 - $0.61 $1,704 - $2,121	-3,478 Reduced 45.68%	4,136 $3,000
Q3 2022 Nov 10, 2022	SELL	$0.0 - $0.93 $0 - $3,878	-4,170 Reduced 35.39%	7,614 $3,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $0.89 $2,381 - $5,576	-6,266 Reduced 34.71%	11,784 $10,000
Q1 2022 May 12, 2022	BUY	$0.58 - $0.86 $2,806 - $4,161	4,839 Added 36.63%	18,050 $11,000
Q4 2021 Feb 14, 2022	BUY	$0.73 - $1.28 $263 - $462	361 Added 2.81%	13,211 $11,000
Q3 2021 Nov 15, 2021	BUY	$0.77 - $4.91 $5,073 - $32,351	6,589 Added 105.24%	12,850 $10,000
Q2 2021 Aug 16, 2021	SELL	$2.18 - $4.66 $51,493 - $110,073	-23,621 Reduced 79.05%	6,261 $29,000
Q1 2021 May 17, 2021	BUY	$1.3 - $3.24 $23,484 - $58,530	18,065 Added 152.87%	29,882 $78,000
Q4 2020 Feb 16, 2021	SELL	$1.01 - $1.77 $10,077 - $17,661	-9,978 Reduced 45.78%	11,817 $16,000
Q3 2020 Nov 16, 2020	SELL	$0.67 - $1.4 $10,583 - $22,114	-15,796 Reduced 42.02%	21,795 $31,000
Q2 2020 Aug 13, 2020	BUY	$0.52 - $0.87 $14,985 - $25,071	28,818 Added 328.49%	37,591 $27,000
Q1 2020 May 15, 2020	BUY	$0.39 - $1.03 $2,171 - $5,734	5,567 Added 173.64%	8,773 $5,000
Q4 2019 Feb 07, 2020	SELL	$0.89 - $1.5 $229 - $387	-258 Reduced 7.45%	3,206 $3,000
Q3 2019 Nov 05, 2019	SELL	$1.04 - $1.51 $604 - $877	-581 Reduced 14.36%	3,464 $4,000
Q2 2019 Aug 13, 2019	BUY	$0.95 - $2.46 $3,842 - $9,950	4,045 New	4,045 $7,000
Q1 2019 May 14, 2019	SELL	$0.69 - $1.47 $184 - $393	-268 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$0.96 - $2.04 $257 - $546	268 New	268 $0

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.